-transparent.png){kind=logo}
Little is understood about the mechanism of acquired resistance to the widely used antineoplastic drug, cisplatin. The cisplatin-resistant murine leukemia L1210 cell line L1210/PAM has an elevated cellular glutathione content, as compared to its sensitive parent cell line, L1210/*. Exposure to D,L-buthionine-S,R-sulfoximine reduced L1210/PAM cells' glutathione content to nearly that of L1210/* cells and abrogated the resistance to cisplatin.
Related Publications
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
July 1990,
Cancer letters,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
December 1993,
Cancer research,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
November 1987,
The Journal of biological chemistry,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
January 2003,
Neoplasma,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
January 1998,
Oncology reports,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
July 1999,
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
January 1996,
Cancer chemotherapy and pharmacology,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
August 2017,
Oncology reports,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
December 1986,
Molecular pharmacology,
R A Hromas, and
P A Andrews, and
M P Murphy, and
C P Burns
August 1987,
Cancer letters,
